Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Biological Chemistry|September 4, 2016
Death-associated Protein Kinase-1 Expression and Autophagy in Chronic Lymphocytic Leukemia Are Dependent on Activating Transcription Factor-6 and CCAAT/Enhancer-binding Protein-βPadmaja Gade, Amy S Kimball, Angela C DiNardo, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2019
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and SubgroupsRobert Z Orlowski, Philippe Moreau, Ruben Niesvizky, et al.
Blood|November 28, 2018
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVORMeletios Dimopoulos, David Siegel, Darrell J White, et al.
American Journal of Hematology|April 26, 2019
Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b studyNoa Biran, David Siegel, Jesus G Berdeja, et al.
Medical Sciences (Basel, Switzerland)|June 24, 2014
NKT Cell Responses to B Cell LymphomaJunxin Li, Wenji Sun, Priyanka B Subrahmanyam, et al.
Biomolecules|May 27, 2026
Natural Killer T Cell Function in Lymphoma PatientsRoshanak Derakhshandeh, Michael S Lee, Yuyi Zhu, et al.
American Journal of Hematology|October 30, 2020
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myelomaMelissa Alsina, Ola Landgren, Noopur Raje, et al.
Leukemia & Lymphoma|April 15, 2021
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphomaWyndham H Wilson, Tycel Phillips, Leslie Popplewell, et al.
Haematologica|July 29, 2021
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomasAjay Major, Justin Kline, Theodore G Karrison, et al.
The Lancet. Oncology|August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
Pageof 3